Genmab obtains important FDA agreement for skin cancer study  

2005.04.22
Genmab, a Copenhagen based biotech company, has reached an agreement with the FDA on the design of Genmab's pivotal study for its HuMax-CD4 antibody for the treatment of skin cancer

Genmab, a Copenhagen based biotech company, has reached an agreement with the US Food and Drug Administration (FDA), on the design of Genmab's pivotal study for its HuMax-CD4 antibody for the treatment of skin cancer. The trial will include patients with the most widespread form of skin cancer who are unresponsive to the standard treatment available today.

Lisa N. Drakeman, managing director of Genmab, says the agreement is an important milestone for the company, and provided that the results with HuMax-CD4 are positive and the research follows the protocol, it could lead to an approval from the FDA.

Genmab creates and develops human antibodies for the treatment of life-threatening and debilitating diseases such as cancer and rheumatoid arthritis. Genmab has partnership agreements with companies such as Roche and Amgen. In addition to Genmab's activities in Denmark, it has operations in Utrecht, Holland and Princeton, New Jersey in the US. The news is reported by financial daily newspaper Børsen and on Genmab's website.

Link > Genmab 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×